🚀 VC round data is live in beta, check it out!
Masimo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Masimo and similar public comparables like Baxter International, Zydus Lifesciences, Bio-Rad Laboratories, Cochlear and more.
Masimo Overview
About Masimo
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Founded
1989
HQ
Employees
9.2K
Website
Financials (LTM)
EV
$10B
Masimo Financials
Masimo reported last 12-month revenue of $2B and EBITDA of $465M.
In the same LTM period, Masimo generated $967M in gross profit, $465M in EBITDA, and had net loss of ($26M).
Revenue (LTM)
Masimo P&L
In the most recent fiscal year, Masimo reported revenue of $2B and EBITDA of $475M.
Masimo expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $967M | XXX | $945M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $465M | XXX | $475M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | ($26M) | XXX | $270M | XXX | XXX | XXX |
| Net Margin | (2%) | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $372M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Masimo Stock Performance
Masimo has current market cap of $9B, and enterprise value of $10B.
Market Cap Evolution
Masimo's stock price is $178.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $9B | 0.0% | XXX | XXX | XXX | $5.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMasimo Valuation Multiples
Masimo trades at 6.3x EV/Revenue multiple, and 20.9x EV/EBITDA.
EV / Revenue (LTM)
Masimo Financial Valuation Multiples
As of April 19, 2026, Masimo has market cap of $9B and EV of $10B.
Equity research analysts estimate Masimo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Masimo has a P/E ratio of (364.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | 20.9x | XXX | 20.5x | XXX | XXX | XXX |
| EV/EBIT | 27.8x | XXX | 21.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | 10.3x | XXX | XXX | XXX |
| P/E | (364.3x) | XXX | 34.6x | XXX | XXX | XXX |
| EV/FCF | 50.8x | XXX | 45.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Masimo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Masimo Margins & Growth Rates
Masimo's revenue in the last 12 month grew by 7%.
Masimo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Masimo's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Masimo's rule of X is 23% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Masimo Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Masimo Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Masimo | XXX | XXX | XXX | XXX | XXX | XXX |
| Baxter International | XXX | XXX | XXX | XXX | XXX | XXX |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Rad Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Cochlear | XXX | XXX | XXX | XXX | XXX | XXX |
| Olympus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Masimo M&A Activity
Masimo acquired XXX companies to date.
Last acquisition by Masimo was on XXXXXXXX, XXXXX. Masimo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Masimo
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMasimo Investment Activity
Masimo invested in XXX companies to date.
Masimo made its latest investment on XXXXXXXX, XXXXX. Masimo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Masimo
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Masimo
| When was Masimo founded? | Masimo was founded in 1989. |
| Where is Masimo headquartered? | Masimo is headquartered in United States. |
| How many employees does Masimo have? | As of today, Masimo has over 9K employees. |
| Who is the CEO of Masimo? | Masimo's CEO is Catherine M. Szyman. |
| Is Masimo publicly listed? | Yes, Masimo is a public company listed on Nasdaq. |
| What is the stock symbol of Masimo? | Masimo trades under MASI ticker. |
| When did Masimo go public? | Masimo went public in 2007. |
| Who are competitors of Masimo? | Masimo main competitors are Baxter International, Zydus Lifesciences, Bio-Rad Laboratories, Cochlear. |
| What is the current market cap of Masimo? | Masimo's current market cap is $9B. |
| What is the current revenue of Masimo? | Masimo's last 12 months revenue is $2B. |
| What is the current revenue growth of Masimo? | Masimo revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Masimo? | Current revenue multiple of Masimo is 6.3x. |
| Is Masimo profitable? | Yes, Masimo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Masimo? | Masimo's last 12 months EBITDA is $465M. |
| What is Masimo's EBITDA margin? | Masimo's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Masimo? | Current EBITDA multiple of Masimo is 20.9x. |
| What is the current FCF of Masimo? | Masimo's last 12 months FCF is $192M. |
| What is Masimo's FCF margin? | Masimo's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Masimo? | Current FCF multiple of Masimo is 50.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.